AstraZeneca Opts In To ROR Gamma T Inhibitor Space With Orca Collaboration
BioMotiv spinout could realize up to $122.5 million under arrangement giving AstraZeneca global option rights to a late-stage preclinical program for producing drugs that regulate production of IL-17.
Just one week after Sanofi entered the ROR gamma T inhibitor drug discovery and development space, AstraZeneca PLC found its way in by signing an exclusive option agreement with Orca Pharmaceuticals Ltd., the first spinout of specialty pharma incubator BioMotiv LLC.
